Objectives: This study was conducted to assess the prevalence of azole resistance in Aspergillus isolates from patients with haematological malignancies or who were undergoing haematopoietic stem cell transplantation and to identify the molecular mechanism of resistance.
Methods: In this 28-month prospective study involving 18 Italian centres, Aspergillus isolates from surveillance cultures were collected and screened for azole resistance, and mutations in the cyp51A gene were identified. Resistant isolates were genotyped by microsatellite analysis, and the allelic profiles were compared with those of resistant environmental and clinical isolates from the same geographical area that had been previously genotyped.
Results: There were 292 Aspergillus isolates collected from 228 patients. The isolates belonged mainly to the section Fumigati (45.9%), Nigri (20.9%), Flavi (16.8%) and Terrei (4.8%). Three isolates showed itraconazole resistance: Aspergillus fumigatus sensu stricto, Aspergillus lentulus (section Fumigati) and Aspergillus awamori (section Nigri). The itraconazole resistance rates were 1% and 1.48% considering all Aspergillus spp. isolates and the Aspergillus section Fumigati, respectively. The prevalence of azole resistance among all the patients was 1.3%. Among patients harbouring A. fumigatus sensu stricto isolates, the resistance rate was 0.79%. The A. fumigatus isolate, with the TR/L98H mutation, was genotypically distant from the environmental and clinical strains previously genotyped.
Conclusions: In this study, the Aspergillus azole resistance rate was 1% (3/292). In addition to A. fumigatus sensu stricto, A. lentulus and A. awamori azole-resistant isolates were identified. Therefore, it is important have a correct identification at the species level to address a rapid therapy better, quickly understand the shift towards cryptic species and have an updated knowledge of the local epidemiology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jgar.2020.01.016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mechanisms of resistance to cell wall and plasma membrane targeting antifungal drugs in candida species isolated in africa.
Expert Rev Anti Infect Ther
January 2025
Pathogenic Yeast Research Group, Department of Microbiology and Biochemistry, University of the Free State, Bloemfontein, South Africa.
Introduction: There is a rise in antifungal resistance as well as the emergence of multidrug resistant fungal pathogens worldwide, including in Africa.
Method: This systematic review summarized the published data on the mechanisms and epidemiology of antifungal resistance in species in Africa between 2000 and early 2024.
Result: Seventeen reports from seven African countries were analyzed but due to the paucity of data, the prevalence of antifungal resistant isolates in Africa could not be estimated.
Antifungal Resistance Patterns of Microsporum canis: A 27-Year MIC Study in Mainland China.
Mycoses
January 2025
Department of Dermatology and Venereology, Peking University First Hospital, Beijing, China.
Background: Microsporum canis, a dermatophyte commonly associated with pets, is a leading cause of severe tinea capitis. The increasing prevalence of antifungal resistance among dermatophytes poses a significant global health challenge.
Objectives: This study aims to define the updated antifungal susceptibility profile of M.
Evaluation of the consumption pattern and efficacy of Linezolid in COVID-19 hospitalized patients in a hospital in Tehran-Iran.
Daru
January 2025
Health Research Center, Life Style Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran.
Background: The inappropriate use of antibiotics increases the costs of treatment, antibiotic resistance, increased disease length and duration of hospital stay.
Objectives: The aim of this study was investigating the pattern of use and effectiveness of the Linezolid in COVID-19 hospitalized patients.
Methods: In this retrospective cross-sectional analytical study was carried out from February 2020 (from the beginning of the pandemic in Iran) to the end of September 2020, 32 COVID-19 patients that used Linezolid were included.
Emerging Antifungal Resistance in : Insights from Susceptibility Profiling and Genetic Mutation Analysis.
Emerg Microbes Infect
January 2025
Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
species, the leading cause of dermatophytosis globally, are increasingly resistant to antifungal treatments, concerns about effective management strategies. In light of the absence of established resistance criteria for terbinafine and azoles, coupled with a dearth of research on resistance mechanisms in , antifungal susceptibility and drug resistance gene diversity were analyzed across 64 , 65 , and 2 isolates collected in China between 2001 and 2024 and 101 published strains. Analyses of the minimum inhibitory concentrations (MICs) of terbinafine, itraconazole, voriconazole, posaconazole, and isavuconazole revealed a concerning increase in with terbinafine resistance, including two novel isolates from China.
View Article and Find Full Text PDFMechanisms of Azole Potentiation: Insights from Drug Repurposing Approaches.
ACS Infect Dis
January 2025
Department of Pharmacy, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200092, China.
The emergence of azole resistance and tolerance in pathogenic fungi has emerged as a significant public health concern, emphasizing the urgency for innovative strategies to bolster the efficacy of azole-based treatments. Drug repurposing stands as a promising and practical avenue for advancing antifungal therapy, with the potential for swift clinical translation. This review offers a comprehensive overview of azole synergistic agents uncovered through drug repurposing strategies, alongside an in-depth exploration of the mechanisms by which these agents augment azole potency.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!